Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

aneously administered GM-CSF in patients with unresectable Stage III (b-c) and Stage IV (M1a-c) melanoma. The primary endpoint is the rate of durable (maintained for six months) objective response. A total of 360 patients will be enrolled (240 to the OncoVEX arm and 120 to the control arm). The study design was agreed with the Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process, which provides agreement with the FDA that the trial's design, clinical endpoints and statistical analysis, if the study is successful, are appropriate to be used as the basis for regulatory approval.

About Metastatic Melanoma

According to the American Cancer Society, more than 8,000 people died in the U.S. of melanoma in 2008. Prevalence of Stage III and Stage IV disease is 120,000 and median survival for Stage IV disease is six months.

Treatment of melanoma depends on the stage of the disease with surgical resection being effective in the early stages of the disease. However, survival rates for the later Stage III and Stage IV patients are poor, reflecting the lack of effective drugs for recurrent or metastatic disease. Current systemic therapies are not generally effective in terms of generating durable responses or in impacting survival. As a result, many patients presenting with metastatic disease are directly enrolled into a clinical trial. The vast majority of experimental therapies to date have failed to show more than a single digit durable response rate.

About OncoVEX

The Company's lead cancer treatment, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus, that works by replicating and spreading within solid tumors (leaving healthy cells unaffected), thereby causing cancer cell death and stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metas
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- In the Friday, December 19 edition of USA ... Technology (HIT) features Konica Minolta, the company announced today. The supplement ... leading healthcare organizations. In addition to the print ... as New York , Chicago ... Minneapolis and San Francisco ...
(Date:12/19/2014)... , Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. ... agreement with MSN Laboratories Pvt. Ltd. ( Hyderabad, ... to commercialize several new ANDAs.  Under the terms of ... products exclusively to Breckenridge for the U.S. market, and ... label.  Breckenridge and MSN have agreed to develop an ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 /PRNewswire/ ...  Sorrento), an oncology company developing new treatments for ... privately-held immuno-oncology company developing proprietary Neukoplast ® ... announced today that the companies have entered into ... CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the treatment ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
(Date:12/22/2014)... China (PRWEB) December 22, 2014 Physicians ... MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), ... , a leading global healthcare consulting firm. MabThera is ... lymphoma (DLBCL), the most common form of NHL. , ... Access and Barriers,” the incidence of NHL in China ...
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
(Date:12/22/2014)... 22, 2014 In recognition of Veteran’s ... to Hero Reward, a local organization that provides services ... , Located on a couple hundred acres in ... offers lodging, world class fishing, hunting, hiking, horseback riding, ... founded several years ago to support U.S. Service men ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once ... to provide logistics and support for one of Dallas’ largest ... long history of giving back to the community in which ... Toy Drive were Whataburger® and 99.5 The Wolf. , There ... Providing gifts to children who would otherwise not receive any ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... 26 HHS Secretary Mike,Leavitt today announced the release ... income homeowners and renters meet home energy costs. The,Low ... to,provide states with heating assistance for the fall and ... cold," Secretary Leavitt said. "These,funds will put states in ...
... Action Committee of,Massachusetts (AAC) today presented written and oral ... variety of bills having to do with privacy,informed consent ... testified in support of H2276,the Public Health Privacy Act, ... balances the public health system,s interest in obtaining health,information ...
... MCLEAN, Va., Sept. 26 Science,Applications International Corporation ... won a new $38 million task order from ... Program -- Joint (TMIP-J). The single-award, cost-plus-fixed-fee ... and three one-year options. The task order was,awarded ...
... SEIU United Healthcare,Workers-West and SEIU Local ... stop Tenet Healthcare Corp. from cutting health ... registered nurses,pharmacists, licensed vocational nurses, respiratory care ... Workers represented by the two unions ...
... As part of its ongoing dedication to,serving military members ... returning presenting sponsor of Fleet Week San Diego, a,month-long ... kicked off its 11th year on Sept. 17 and ... highlight the historical, economic and,cultural importance of military personnel ...
... 26 Residents from Metropolitan,Jewish Geriatric Center recently ... performed before Yom Kippur. (Photo: http://www.newscom.com/cgi-bin/prnh/20070926/NYW148 ... live chicken (a rooster for a man and ... one,s head while reciting a prayer.,This ritual is ...
Cached Medicine News:Health News:HHS Provides Over $131 Million In Energy Assistance 2Health News:AIDS Action Committee Testifies to Protect the Privacy of People Seeking Healthcare in Massachusetts 2Health News:SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint 2Health News:Unions File Charges Against Tenet Healthcare Corporation, Three Northern California Hospitals 2Health News:TriWest On Deck to Support Fleet Week San Diego 2
... and its specifically designed reagents, allows ... same sample, multiple analytes. This unique ... of laboratories willing to simplify and ... routine, as well as to reduce ...
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system....
... thrombectomy never handled like this ... in mind, the Spiroflex catheters ... tip and hydrophilic coating provide ... Glide in with ease and ...
... is the only online source of nationally ... critical care nurses and other healthcare professionals., ... so you can take them at your ... certificate is issued upon course completion. The ...
Medicine Products: